| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
25,464 |
24,188 |
$1.66M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
3,935 |
3,914 |
$507K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,124 |
5,890 |
$266K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,859 |
4,824 |
$166K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,657 |
1,655 |
$143K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
739 |
733 |
$109K |
| 99443 |
|
1,024 |
989 |
$77K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
318 |
317 |
$29K |
| 62323 |
|
518 |
469 |
$29K |
| 64493 |
|
376 |
316 |
$26K |
| 64494 |
|
357 |
294 |
$14K |
| 99215 |
Prolong outpt/office vis |
109 |
103 |
$8K |
| 64635 |
|
47 |
42 |
$6K |
| 72275 |
|
234 |
201 |
$4K |
| 64483 |
|
45 |
39 |
$3K |
| 64495 |
|
77 |
63 |
$3K |
| 64636 |
|
46 |
41 |
$2K |
| 99205 |
Prolong outpt/office vis |
14 |
14 |
$2K |
| 62321 |
|
19 |
15 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13 |
13 |
$839.54 |
| 99406 |
|
129 |
120 |
$738.17 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
116 |
113 |
$700.73 |
| 20611 |
|
12 |
12 |
$664.51 |
| 64484 |
|
14 |
12 |
$430.94 |
| 80305 |
|
40 |
40 |
$200.48 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
153 |
149 |
$173.34 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
109 |
106 |
$85.31 |
| G0030 |
Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user |
12 |
12 |
$0.02 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
86 |
84 |
$0.00 |
| J3490 |
Unclassified drugs |
72 |
71 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
80 |
79 |
$0.00 |
| 1006F |
|
14 |
14 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
108 |
103 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
45 |
44 |
$0.00 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
32 |
32 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
655 |
624 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
421 |
402 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
54 |
54 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
16 |
16 |
$0.00 |
| 4040F |
|
14 |
14 |
$0.00 |
| 1124F |
|
27 |
27 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
64 |
64 |
$0.00 |